NCT03522129View on ClinicalTrials.gov

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

February 6, 2019

Study Completion Date

February 6, 2019

Conditions
Alzheimer Disease
Interventions
DRUG

CT1812

Active Study Drug

DRUG

Placebo

Non-active study drug

Trial Locations (2)

19104

University of Pennsylvania, Philadelphia

07724

Clinilabs Drug Development Corporation, New York

Sponsors
All Listed Sponsors
lead

Cognition Therapeutics

INDUSTRY

NCT03522129 - Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter